Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.chom.2021.03.002 http://scihub22266oqcxt.onion/10.1016/j.chom.2021.03.002 33705729!7934674!33705729     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell+Host+Microbe 2021 ; 29 (4): 529-539.e3 Nephropedia Template TP {{tp|p=33705729|t=2021. SARS-CoV-2 variant B 1 1 7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines |pdf=|usr=}}{{33705729}} gab.com Text SARS-CoV-2 variant B 1 1 7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines JO: Cell Host Microbe http://www.kidney.de/pget.php?&tw=1&pmid=33705729 #FOAvip All current vaccines for COVID-19 utilize ancestral SARS-CoV-2 spike with the goal of generating protective neutralizing antibodies. The recent emergence and rapid spread of several SARS-CoV-2 variants carrying multiple spike mutations raise concerns about possible immune escape. One variant, first identified in the United Kingdom (B.1.1.7, also called 20I/501Y.V1), contains eight spike mutations with potential to impact antibody therapy, vaccine efficacy, and risk of reinfection. Here, we show that B.1.1.7 remains sensitive to neutralization, albeit at moderately reduced levels ( approximately sim;2-fold), by serum samples from convalescent individuals and recipients of an mRNA vaccine (mRNA-1273, Moderna) and a protein nanoparticle vaccine (NVX-CoV2373, Novavax). A subset of monoclonal antibodies to the receptor binding domain (RBD) of spike are less effective against the variant, while others are largely unaffected. These findings indicate that variant B.1.1.7 is unlikely to be a major concern for current vaccines or for an increased risk of reinfection. Twit Text FOAVip SARS-CoV-2 variant B 1 1 7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines ????Cell Host Microbe http://www.kidney.de/pget.php?&tw=1&pmid=33705729 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33705729 #FOAvip English Wikipedia <ref>{{Cite pmid|33705729}}</ref> SARS-CoV-2 variant B 1 1 7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines #MMPMID33705729 Shen X; Tang H; McDanal C; Wagh K; Fischer W; Theiler J; Yoon H; Li D; Haynes BF; Sanders KO; Gnanakaran S; Hengartner N; Pajon R; Smith G; Glenn GM; Korber B; Montefiori DC Cell Host Microbe 2021[Apr]; 29 (4): 529-539.e3 PMID33705729show ga All current vaccines for COVID-19 utilize ancestral SARS-CoV-2 spike with the goal of generating protective neutralizing antibodies. The recent emergence and rapid spread of several SARS-CoV-2 variants carrying multiple spike mutations raise concerns about possible immune escape. One variant, first identified in the United Kingdom (B.1.1.7, also called 20I/501Y.V1), contains eight spike mutations with potential to impact antibody therapy, vaccine efficacy, and risk of reinfection. Here, we show that B.1.1.7 remains sensitive to neutralization, albeit at moderately reduced levels ( approximately sim;2-fold), by serum samples from convalescent individuals and recipients of an mRNA vaccine (mRNA-1273, Moderna) and a protein nanoparticle vaccine (NVX-CoV2373, Novavax). A subset of monoclonal antibodies to the receptor binding domain (RBD) of spike are less effective against the variant, while others are largely unaffected. These findings indicate that variant B.1.1.7 is unlikely to be a major concern for current vaccines or for an increased risk of reinfection. |2019-nCoV Vaccine mRNA-1273[MESH] |Adolescent[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antibodies, Monoclonal/immunology[MESH] |Antibodies, Neutralizing/*immunology[MESH] |Antibodies, Viral/*immunology[MESH] |COVID-19 Vaccines/*immunology[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Mutation[MESH] |Neutralization Tests[MESH] |SARS-CoV-2/*immunology[MESH] |Spike Glycoprotein, Coronavirus/genetics/immunology[MESH]SARS-CoV-2 variant B 1 1 7 is susceptible to neutralizing antibodies e(epmc).pdf DeepDyve Pubget Overpricing